vimarsana.com

Page 4 - Bayesian Optimal Interval News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Vaccinex Reports Second Quarter 2023 Financial Results and Provides Corporate Update

Phase 1/2a SIGNAL-AD Study of Pepinemab in Alzheimer’s Disease Achieves Full Accrual Expect to Complete 12-months treatment in June, 2024 Promising Interim Results for KEYNOTE-B84 Phase 2 Trial. -Today at 08:11 am- MarketScreener

United statesAlbertd friedbergVaccinex rochesterJohn mullalyMaurice zaudererExchange commissionAlzheimer drug discovery foundationPlatform technologyVaccinex incCo incUniversity of rochesterCoherus biosciences incMerck kgaAlzheimer associationUniversity of rochester cancer centerLifesci advisors

Vaccinex Reports Second Quarter 2023 Financial Results and Provides Corporate Update - Vaccinex (NASDAQ:VCNX)

Phase 1/2a SIGNAL-AD Study of Pepinemab in Alzheimer's Disease Achieves Full Accrual Expect to Complete 12-months treatment in June, 2024 Promising Interim Results for KEYNOTE-B84 Phase 2 Trial in Head and Neck Cancer

United statesVaccinex rochesterAlbertd friedbergJohn mullalyMaurice zaudererAlzheimer associationVaccinex incCo incMerck coCoherus biosciences incExchange commissionUniversity of rochester cancer centerLifesci advisorsMerck kgaaUniversity of rochesterMoffitt cancer center

BLU-945 Plus Osimertinib Has Favorable Tolerability, Warrants Further Development in EGFR+ NSCLC

BLU-945 alone or in combination with osimertinib demonstrated early signals of clinical activity and was well tolerated in heavily pretreated patients with EGFR-mutant non–small cell lung cancer.

United statesYasiry elaminBristol myers squibb medarexSpectrum pharmaceuticalsUniversity of texas md anderson cancerDivision of cancer medicineNeck medical oncologyCancer medicineBayesian optimal intervalTurning pointBlueprint medicinesElevation oncologyPrecision therapeuticsBlu 945 alone or in combination with osimertinibHeavily pretreated patients with egfr mutant non small cell lung cancerSymphony trial

Galapagos NV: Galapagos to showcase CAR-T point-of-care manufacturing and initial Phase 1/2 CLL data with CD19 CAR-T candidate, GLPG5201, at the EHA 2023 congress

All 7 out of 7 eligible patients with relapsed/refractory chronic lymphocytic leukemia (rrCLL), with or without Richter's Transformation (RT), responded to treatment (Objective Response Rate of 100%)1

Region flamandeMecklenburg vorpommernDaniel estbanSergi betriuJeevan shettyMarieke vermeerschSandra cauwenberghsNuria martinez cibrianVan gijselJulio delgadoChristian jacquesMercedes montoroStefan klotterValentin ortiz maldonadoLeticia alserawanMargotj pont

Galapagos to showcase CAR-T point-of-care manufacturing and initial Phase 1/2 CLL data with CD19 CAR-T candidate, GLPG5201, at the EHA 2023 congress

All 7 out of 7 eligible patients with relapsed/refractory chronic lymphocytic leukemia , with or without Richter’s Transformation , responded to treatment 1 GLPG5201 showed no cytokine. | June 5, 2023

Region flamandeSandra cauwenberghsMargotj pontLeticia alserawanMarieke vermeerschNuria martinez cibrianDaniel estbanMercedes montoroVan gijselJulio delgadoJeevan shettyChristian jacquesValentin ortiz maldonadoSergi betriuExchange commissionEuropean hematology association

vimarsana © 2020. All Rights Reserved.